<DOC>
	<DOC>NCT00810732</DOC>
	<brief_summary>This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.</brief_summary>
	<brief_title>Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Has stage 15 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) with proteinuria, including any of the following aetiologies: immunoglobulin (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy. Required peritoneal dialysis or haemodialysis. Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>This study is being conducted to evaluate sitaxsentan dosing in subjects with chronic kidney disease.</keyword>
	<keyword>B1321005</keyword>
</DOC>